Viewing nowCombinationSambica HCT Tablet 5/20/12.5 mg
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.

MFDS item code 201902020 · Approved 2019.04.03 · Insurance code 642307610
Treatment of essential hypertension not controlled by combination therapy
Combination therapy using amlodipine and olmesartan medoxomil is used in cases where blood pressure is not sufficiently controlled among patients with essential hypertension. These drugs act by dilating blood vessels and lowering blood pressure, and combining the two medications allows for more effective blood pressure control. Proper management of blood pressure is very important to reduce the risk of cardiovascular diseases. This combination therapy helps to stably improve the patients' blood pressure and maintain their health.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine and olmesartan medoxomil as monotherapy or combination therapy). However, if blood pressure is not adequately controlled with amlodipine and olmesartan medoxomil combination therapy, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 5/40mg or with this medicine at 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine at 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil combination therapy at 10/40mg or with this medicine at 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine at 5/40/25mg or 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Since experience with this medicine in elderly patients, particularly those aged 75 years and older, is very limited, monitor patients very carefully when administering this medicine.
Safety and efficacy have not been established in pediatric patients under 18 years of age; therefore, administration of this medicine is not recommended.
This drug may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, and therefore, should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to this drug or any of its components, pregnant or breastfeeding women, and patients with severe hypotension or heart, kidney, or liver diseases should not use this drug. Patients with reduced blood volume or poor kidney function, patients with liver disease, etc., should be particularly careful when using this drug, and blood pressure, kidney function, and electrolyte levels should be regularly monitored during treatment. This drug lowers blood pressure, and may cause symptoms of hypotension, as well as dizziness or drowsiness, so caution should be exercised when driving or operating dangerous machinery. This drug may interact with other medications, therefore, it is important to consult with a doctor or pharmacist when taking it alongside lithium, non-steroidal anti-inflammatory drugs (NSAIDs), or other antihypertensive agents. Long-term use of this drug may lead to electrolyte imbalances, so potassium, sodium, calcium levels, etc., should be periodically checked through blood tests. Women who are pregnant or planning to become pregnant should consult with healthcare professionals before taking this drug, and breastfeeding women should also avoid taking this drug. The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age, so its use is not recommended. In the case of overdose, symptoms such as hypotension and palpitations may occur, so immediate medical assistance should be sought. This drug should be stored in a tightly closed container to protect it from light and moisture and kept out of reach of children, and it is recommended not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to protect it from air and moisture and should be stored at room temperature between 1 to 30 degrees Celsius. By storing it this way, the drug's effectiveness can be maintained and deterioration prevented.
White-orange round film-coated tablets
30 tablets (10 tablets/Alu-Alu × 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Daicel Corporation (Co., Ltd.)
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
HanKook Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.